Brief: Essex Bio-Technology Says Unit Obtained Approval From State Drug Administration For A Product
Aug 22 (Reuters) - Essex Bio-Technology Ltd 1061.HK :
* GETS APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE
SINGLE-DOSE
SODIUM HYALURONATE EYE DROPS IN CHINA
* SAYS UNIT OBTAINED APPROVAL FROM STATE DRUG ADMINISTRATION
FOR
PRODUCT
Source text for Eikon: ID:nHKSbxnV7y
Further company coverage: 1061.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share